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Abstract
Background:  This study was undertaken to examine the relationship between the tumor
suppressor gene p53 and the nuclear signaling protein beta-catenin during bone differentiation.
Cross talk between p53 and beta-catenin pathways has been demonstrated and is important during
tumorigenesis and DNA damage, where deregulation of beta catenin activates p53. In this study,
we used estrogen treatment of osteoblasts as a paradigm to study the relationship between the
two proteins during osteoblast differentiation.
Results: We exposed osteoblast-like ROS17/2.8 cells to 17-beta estradiol (E2), in a short term
assay, and studied the cellular distribution and expression of beta-catenin. We found beta-catenin
to be up regulated several fold following E2 treatment. Levels of p53 and its functional activity
mirrored the quantitative changes seen in beta-catenin. Alkaline phosphatase, an early marker of
osteoblast differentiation, was increased in a manner similar to beta-catenin and p53. In order to
determine if there was a direct relationship between alkaline phosphatase expression and beta-
catenin, we used two different approaches. In the first approach, treatment with LiCl, which is
known to activate beta-catenin, caused a several fold increase in alkaline phosphatase activity. In
the second approach, transient transfection of wild type beta-catenin into osteoblasts increased
alkaline phosphatase activity two fold over basal levels, showing that beta catenin expression can
directly affect alkaline phosphatase expression. However increase in beta catenin activity was not
associated with an increase in its signaling activity through TCF/LEF mediated transcription.
Immunofluorescence analyses of p53 and beta-catenin localization showed that E2 first caused an
increase in cytosolic beta-catenin followed by the accumulation of beta-catenin in the nucleus.
Nuclear p53 localization was detected in several cells.
Expression of p53 was accompanied by distribution of beta-catenin to the cytoplasm and cell
borders. A sub population of cells staining strongly for both proteins appeared to be apoptotic.
Conclusion:  These results suggest that interactions between p53 and beta-catenin signaling
pathways may play a key role in osteoblast differentiation and maintenance of tissue homeostasis.
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Introduction
The organization of cells in tissues and organs is control-
led by molecular control mechanisms that allow cells to
interact with their neighboring cells and the extra cellular
matrix. Cell-cell recognition and adhesion are critical
processes in development, differentiation and the mainte-
nance of tissue architecture. The cadherins family of Ca2+-
dependent cells and their associated molecules such as
beta-catenin are major components of the cellular adhe-
sion machinery and play central roles in these various
processes [1]. The cadherins are trans-membrane proteins
that mediate Ca2+ dependent cell-cell adhesion. Beta cat-
enin is a multifunctional protein which associates with
the intracellular domain of cadherins. In addition to pro-
viding a physical link between cells, these adherent junc-
tional proteins influence various signaling pathways.
Beta-catenin is an important component of the Wnt /
Wingless signaling pathway and can act as a transcription
factor in the nucleus by serving as a co activator of the
lymphoid enhancer factor (LEF)/TCF family of DNA-
binding proteins [2].
The p53 tumor suppressor gene acts as a guardian of the
genome and a loss of its function is seen in a wider variety
of cancers [3]. P53 acts by sensing DNA damage and
directing the cell to arrest or undergo apoptosis [1,3]. In
this way, p53 is thought to prevent the excessive accumu-
lation of mutations that could give rise to malignancies.
However, p53 activities may not be limited to tumor sup-
pressor functions. Accumulating evidence suggests that
p53 function may be critical during differentiation of var-
ious tissues and organs [4-7]. Defects in p53-null embryos
have been reported, suggesting that p53 may have a role
in tissue organization during development [8,9]. We have,
in previous studies, demonstrated a role for p53 in oste-
oblast differentiation and expression of the bone specific
protein osteocalcin [10]. In studies with p53 null and het-
erozygous mice, we have also shown that a decrease in
p53 expression interferes with the ability of osteoblasts to
express osteocalcin [11]. During in vitro osteoblast differ-
entiation, proliferation is followed by matrix deposition
and mineralization. Alkaline phosphatase is generally
seen as an early marker of osteoblast differentiation, while
osteocalcin is considered a late marker. In our studies with
estrogen, we have shown p53 to be up regulated and its
activity to be associated with cell cycle arrest and expres-
sion of osteoblast differentiation markers rather than
apoptosis [12,13].
Cross talk between p53 and beta-catenin pathways has
been demonstrated and appears to be especially impor-
tant during tumorigenesis and DNA damage, where dereg-
ulation of beta catenin is known to activate p53 [14,15].
Because of the importance of the cadherins and beta-cat-
enin in tissue differentiation, we wanted to determine if
this type of cross talk with p53 exists in osteoblasts under
physiological conditions. We observed expression of sev-
eral apoptosis-related and cell cycle arrest proteins during
short term treatment of bone cells with estrogen [13].
Expression of several caspases have been shown to be
required for expression of bone markers during osteoblast
differentiation [16]. Treatment with 17-beta estradiol did
not result in any appreciable apoptotic cell death [12]. In
studies reported here, we investigated if 17-beta estradiol
could modulate the expression and subcellular distribu-
tion of beta catenin and how it might relate to p53
expression.
Results
17-Beta estradiol (E2) up regulates expression of beta-
catenin in osteoblastic osteosarcoma cells
ROS17/2.8 cells stably expressing 13 copies of a p53 bind-
ing sequence (ROS-PG13CAT) fused to a chlorampheni-
col acetyl transferase (CAT) gene were used to study effects
of estrogen on changes in endogenous p53 functional
activity. Binding of endogenous p53 to the PG-13CAT
sequence and subsequent activation of gene expression
was studied by analyzing CAT activity as described in pre-
vious studies [17]. In all other aspects this cell line is rep-
resentative of ROS 17/2.8 cells an osteoblastic
osteosarcoma line that is used extensively to study osteob-
last differentiation. These cells were treated with E2 for
different lengths of time as described under Methods and
the resultant protein was separated on SDS PAGE and ana-
lyzed by western blotting. As may be seen in Figure 1A, an
increase in beta-catenin expression occurred within 6 h of
treatment and peaked at 16 h of E2 treatment followed by
a drop and a second peak during 48 h after E2 treatment.
The first increase was less dramatic than the second
increase in beta-catenin (10 vs 30 fold increase).
P53 functional activity parallels changes in beta-catenin 
expression during E2 treatment
P53 function was monitored by measuring CAT activity in
ROS-PG-13 cells. As may be seen in Figure 1B, p53 tran-
scription activating activity was increased about 4-fold 16
h after E2 treatment followed by a drop and an increase
corresponding to the change seen in beta-catenin at 48 h
interval (about 17-fold). P53 expression is known to
accompany beta-catenin activation and is also thought to
be critical in the regulation of beta catenin function [15].
P53 expression was also measured by western blot analy-
sis and was found to be high after 16 h and remained high
until 48 h of E2 treatment (not shown).
Alkaline Phosphatase, an early marker of bone 
differentiation is increased during treatment with 17-B-
estradiol
Alkaline phosphatase activity was measured during the
same time intervals using a colorimetric assay. WhileCancer Cell International 2005, 5:24 http://www.cancerci.com/content/5/1/24
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17-beta-estradiol treatment increases the amount of beta-catenin in ROS-PG13 cells Figure 1
(A) 17-beta-estradiol treatment increases the amount of beta-catenin in ROS-PG13 cells: Osteoblasts were treated with 10-11 
M E2 for the times indicated and harvested for protein. The resulting protein lysates were subjected to western blot analysis of 
beta-catenin protein and beta-tubulin to monitor equal loading. The intensity of the bands was analyzed using a phosphorim-
ager and results were normalized to beta-tubulin (loading control). A representative blot is shown. (B) Increase in p53 trans-
activating activity mirrors changes in beta-catenin. Equal amounts of E2 treated protein lysates described above were also 
subjected to a CAT assay to measure functional activity of endogenous p53 as described under methods. The resulting activity 
was plotted as fold change when compared to zero time (no treatment). The results represent mean ± SEM of 3 independent 
experiments in triplicates. (C) Alkaline phosphatase activity during E2 treatment: Enzyme activity was measured using a color-
imetric assay as described under methods using the protein lysate described above. Values represent fold change when com-
pared to control. Values represent mean ± SEM with an n of 3.
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alkaline phosphatase increased steadily with E2 treat-
ment, the enzyme activity showed a clear spike during the
48 h interval (Figure 1C). While initial induction of alka-
line phosphatase activity occurred with an increase in
beta-catenin activity, the subsequent boost to its activity
was seen during 48 h corresponding to the large increase
in beta-catenin activity.
Is there a direct relationship between beta-catenin 
expression and alkaline phosphatase activity?
In order to determine if an increase in beta-catenin
nuclear signaling activity is associated with increased alka-
line phosphatase activity, we used a LiCl treatment as a
model for beta-catenin activation. Treatment with LiCl is
known to inhibit GSK activity, which is critical for phos-
phorylation and inactivation of beta-catenin function
[18]. Immunofluorescent staining for beta-catenin
revealed a transient increase in beta-catenin expression in
the nuclei of ROS-PG-13 in 24 h 10 mM LiCl treated cells
but not in the control NaCl treated cells (not shown). Pro-
tein lysates from the cells similarly treated with either LiCl
or NaCl were tested for alkaline phosphatase activity. As
may be seen in Figure 2, LiCl treated cells showed an
increase in alkaline phosphatase activity 24 h after treat-
ment, compared to a less than 2-fold activation in the
NaCl treated cells (Figure 2).
Transient overexpression of wild type beta-catenin in 
ROS-PG13 cells increases alkaline phosphatase activity as 
well as p53 transcriptional activity
In order to determine if over-expression of beta-catenin
produced similar effects on alkaline phosphatase, we tran-
siently transfected a wild type beta-catenin plasmid into
ROS-PG13 cells. Control cells were transfected with non-
specific DNA. Alkaline phosphatase activity was measured
in the control, mock-transfected and beta-catenin-trans-
fected cells 24 h later. There was a small but statistically
significant increase in alkaline phosphatase activity in
beta catenin transfected cells when compared to cells that
received non-specific DNA (Figure 3A). The same experi-
ment was also repeated with a constitutively active beta-
catenin (B-catenin S33Y) and similar results were
obtained (not shown) suggesting that beta-catenin expres-
sion facilitates alkaline phosphatase expression in rat
osteoblasts.
Protein lysates from the transiently transfected cells were
subjected to CAT assay for determination of p53 func-
tional activity during the same time period. P53 activity
was 5 fold higher in cells transfected with wild type beta-
catenin when compared to control cells (Figure 3B),
showing that a parallel increase in p53 activity may not be
limited to conditions of DNA damage but also occurs
under physiological conditions.
Subcellular distribution of beta-catenin during treatment
In order to determine the localization of beta-catenin dur-
ing the treatment protocol, we conducted immunofluo-
rescence analyses of estrogen treated cells (Figure 4). Cells
were grown to confluency and switched to 2% charcoal
treated media for 24 h before exposure to 17-beta estra-
diol. At the start of experiment (0 time), beta-catenin
staining was only seen at the adherent junctions between
cells and was undetectable intracellularly. 24 h after treat-
ment with 17-beta estradiol, there was a dramatic increase
in the amount of beta-catenin within the cells; most of the
beta-catenin appeared to be in the cytoplasm and peri
nuclear region. By 48 h strong staining for beta-catenin
could be detected within the nucleus of a significant
number of cells.
No change in beta-catenin transcriptional activity during 
E2 treatment
Since we observed nuclear staining of beta-catenin, exper-
iments were carried out to determine if beta-catenin sign-
aling through TCF/LEF family of transcriptional factors
was activated. We transiently transfected the wild type
TCF/LEF response elements (TOPFLASH) or the mutant
sequence (FOPFLASH) followed by treatment with E2
LiCl treatment of ROS-PG13 cells leads to activation of alka- line phosphatase expression Figure 2
LiCl treatment of ROS-PG13 cells leads to activation of alka-
line phosphatase expression. Protein lysates were prepared 
from cells treated with 10 mM LiCl or 10 mM NaCl and har-
vested after the times indicated. Equal amounts of protein 
extracts were used to measure alkaline phosphatase (AP) 
activity using p-nitro phenol phosphate as substrate at 420 
nm and the relative activity of LiCl treated samples to NaCl 
treated controls is shown. The experiment represents mean 
± SEM. n = 3 per treatment group.
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treatment. No significant change in luciferase activity was
noted during E2 treatment (Figure 5). The validity of the
assay was checked using LiCL treatments (Figure 5 insert).
These results indicate that endogenous beta-catenin sign-
aling is not activated during E2 treatment even though the
expression of beta-catenin was observed in the nuclei of
treated cells.
p53 expression during 17-beta estradiol treatment
The patterns of p53 distribution were also monitored by
immunostaining. Immunofluorescence staining for p53
also showed a heterogeneous pattern. P53 expression was
high within the nucleus in a number of isolated cells.
Among the cells that stained strongly for p53, some of
them were apoptotic and counter staining with Hoescht
reagent showed a pyknotic nucleus. In other cases strong
Transient transfection of wild type beta-catenin into ROS-PG-13 cells increases alkaline phosphatase and p53 functional activity Figure 3
(A) Transient transfection of wild type beta-catenin into ROS-PG-13 cells increases alkaline phosphatase and p53 functional 
activity. Following transfection with the beta-catenin or control DNA, cells were lysed and equal amount of protein lysates 
were used to measure alkaline phosphatase activity. Enzyme activity was normalized to the mock transfected controls and 
reported as fold change. Data represents mean ± SEM of n = 4. *p < 0.05 versus control. (B) Transient transfection of wild 
type beta-catenin into ROS-PG-13 cells increases alkaline phosphatase and p53 functional activity. Lysates from the above 
experiment was also used to measure p53 activity by CAT assay. Equal amounts of protein were used and the resulting CAT 
activity is reported as a fold change over control levels. These experiments represent mean ± SEM of n = 4 ** p < 0.05 versus 
control.
Control + Beta- catenin (WT) 
0.0
0.5
1.0
1.5
2.0
A
l
k
a
l
i
n
e
 
P
h
o
s
p
h
a
t
a
s
e
 
 
(
F
o
l
d
 
C
h
a
n
g
e
)
Control + Beta-catenin (WT)
0.0
0.5
1.0
1.5
2.0
2.5
p
5
3
 
f
u
n
c
t
i
o
n
a
l
 
a
c
t
i
v
i
t
y
(
F
o
l
d
 
 
C
h
a
n
g
e
) **
*Cancer Cell International 2005, 5:24 http://www.cancerci.com/content/5/1/24
Page 6 of 11
(page number not for citation purposes)
staining was evident in nuclei that looked
morphologically normal. P53's presence in the nucleus
was also confirmed with western blots of cytoplasmic and
nuclear fractions (not shown). Its presence in the nucleus
correlated with its functional activity as measured by the
CAT assay.
A better understanding of the relationship between the
two proteins was evident when we stained simultaneously
for both proteins and a representative field is shown in fig-
ure 6. Three types of association were evident. Strong
staining of nuclear p53 was accompanied by beta-catenin
in the cell borders (arrows). When both proteins were
present in the nucleus, the cell was generally apoptotic
(broken arrows). When intracellular staining for beta
catenin was strong it was mostly contained in the cyto-
plasm when p53 decorated the nucleus (arrow head).
Discussion
In previous studies, we have shown the tumor suppressor
gene p53 to be up regulated by estrogen and to be
important for differentiative functions in bone [12,13]. In
the studies reported here, we show that beta-catenin
expression is increased during estrogen treatment of oste-
oblasts. This large increase in beta-catenin expression that
we observed may be the result of either a direct increase in
gene expression, or from stabilization of cytosolic beta-
catenin. With regard to the latter possibility it is worth
noting that in other cell types, estrogen has been shown to
inhibit GSK activity which results in the stabilization of
beta-catenin [18].
The association of beta catenin activation with increases
in alkaline phosphatase expression is also very interesting,
but not completely new. This association has been
recently detected in several cell types where alkaline phos-
phatase plays a role in differentiated behavior of the cell
[19-21]. Recent studies have implicated the wnt signaling
pathway and beta-catenin in the regulation of alkaline
phosphase expression in osteoblasts [21]. It appears that
beta-catenin is able to increase alkaline phosphatase
albeit indirectly, because no TCF binding sites have been
detected within the alkaline phosphatase gene [22].
The role of p53 in the regulation of beta-catenin is best
understood under conditions of DNA damage and tumor-
igenesis [15]. Stabilization of beta-catenin has been
observed to cause stabilization of p53 through inhibition
of its degradation [14,23,24]. While it is possible that
beta-catenin results in the stabilization of p53, the result-
ing increase in p53 is not responsible for apoptosis, an
activity that is regulated by p53 during DNA damage.
Instead, under physiological conditions, p53 appears to
monitor the environment such that an abnormal increase
in beta catenin within the nucleus results in apoptosis,
while in other cells the presence of p53 in the nucleus pre-
vents the accumulation of beta-catenin. Beta catenin
under these conditions appears to be relegated to the
plasma membrane.
In the studies reported here we show treatment with 17-
beta estradiol increases expression of beta-catenin and
cause its migration in to the nucleus. Estrogen may medi-
ate this effect by its action on GSK activity as seen in other
tissues [25]. However, beta-catenin expression in the
nucleus does not result in the activation of its signaling
through TCF/LEF transcription factor binding sites. There
are several likely reasons for this observation. As has been
noted earlier, the level of signaling through the canonical
Beta-catenin expression during E2 treatment Figure 4
Beta-catenin expression during E2 treatment: Immunostain-
ing of E2 treated ROS-PG13 with anti-beta-catenin antibody 
demonstrates its localization within the cells at 24 and 48 h 
after treatment. Cells were grown on cover slips and treated 
with 10-11 M 17-beta estradiol in 2% charcoal treated serum 
containing media for the different lengths of time indicated. 
Control cells were grown in 2% charcoal treated serum con-
taining media. Other details are as described under methods.Cancer Cell International 2005, 5:24 http://www.cancerci.com/content/5/1/24
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pathway may be low and below detection limits using
TCF/LEF reporter constructs [26]. It is also possible that
beta-catenin may not directly act through the Wnt canon-
ical pathway, but crosstalk with other pathways to gener-
ate a response. It has been shown that beta-catenin
signaling does not function independently but synergizes
with morphogens like BMP-2 to induce the early bone
phenotypes in undifferentiated cells [21,22]. In a similar
manner, estrogen treatment has been observed to enhance
the binding of beta-catenin to estrogen receptors alpha
and beta in human colon and breast cancer cells [27] and
also participate in the transactivation of estrogen respon-
sive genes. This suggests that beta-catenin may function as
a common mediator of different bone specific agents to
induce early bone phenotype. In this context it is interest-
ing that beta-catenin and LEF1 repress expression of the
osteocalcin gene, a late marker of the bone phenotype
[28].
While the role of estrogen as bone-protective anabolic
agent is well established, the mechanism of action is only
now being understood at the molecular level [29,30].
Increase in beta-catenin expression during E2 treatment does not result in beta-catenin signaling through TCF/LEF response  elements in ROS-PG13 cells Figure 5
Increase in beta-catenin expression during E2 treatment does not result in beta-catenin signaling through TCF/LEF response 
elements in ROS-PG13 cells. Cells were transfected with TopFlash (wild type promoter) and FopFlash (mutant promoter) luci-
ferase reporters in 2% media, and E2 treatment was started three hours later. E2 treatments were staggered during the 48 h 
interval and all cells were harvested after 48 h after the indicated time of exposure to the hormone. Mutant FopFlash activity 
was unchanged during the treatment and is not shown. LiCl treatment was carried out to demonstrate the validity of the assay 
(Inset). Cells were exposed to LiCl or NaCl 24 h after transfection for 16 h. In both these experiments luciferase activity was 
measured in cell lysates using equal amounts of protein. Experiments represent average ± SEM of triplicate measurements.
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Estrogen affects osteoblasts by non genotropic mecha-
nisms that go to increase the life span of the osteoblasts by
its action on plasma membrane signaling proteins [31].
Antiapoptotic mechanism by estrogen is transient in oste-
oblasts and it is not clear if p53 plays a role in this process.
In a manner similar to estrogen receptors, p53 has been
shown to bind beta-catenin resulting in its stabilization
and transcriptional activation [23]. P53 is also able to
inhibit expression of TCF-4 by directly binding to the pro-
moter of the gene [32]. This type of regulation may be
important to maintain cell-cell interactions and prevent
apoptosis. These types of cross signaling may be relevant
and important for osteoblast differentiation as opposed to
osteoblast proliferation and may critically depend on the
cellular environment. P53 is known to interact with a
plethora of proteins [33] and these interactions may
determine the final outcome for the cell. P53's ability to
sense the environment allows for cell cycle arrest and dif-
ferentiation under some circumstances and apoptosis in
other instances. Expression of alkaline phosphatase a dif-
ferentiation marker in bone may be facilitated by beta-cat-
enin nuclear activity. However once alkaline phosphatase
is increased, p53 activity may be critical to maintain the
differentiated behavior of the cell by making sure beta-cat-
enin is retained at cell borders rather than within the
nucleus. Further studies are required to understand how
the interactions between estrogen receptors, beta-catenin,
p53 and related proteins facilitate the differentiation
process.
Conclusion
Our data shows that beta-catenin activity is modulated
during estrogen induced osteoblast differentiation and its
increase is associated with an increase in p53 and alkaline
Immunohistochemical staining of beta-catenin and p53 Figure 6
Immunohistochemical staining of beta-catenin and p53. Cells were treated with 10-11 M 17-beta estradiol for 48 h as described 
under methods and stained for p53 (green) and beta-catenin (red) using specific antibodies. Panel A shows cells strongly stain-
ing for both proteins in the nucleus (broken arrow), strong p53 staining in the nucleus and beta-catenin at the plasma mem-
brane (solid arrows) and strong staining of p53 in the nucleus with beta-catenin relegated to the cytoplasm (arrow head). B and 
C show apoptotic cells with strong staining of both proteins.
A B
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phosphatase. The cellular localization of endogenous p53
and beta-catenin appears be mutually exclusive during
estrogen treatment and reflects the role of p53 in regulat-
ing growth and differentiation.
Methods
Establishment of cell lines
The cell line ROS 17/2.8, a rat osteosarcoma cell line, was
kindly provided by Dr. G. Rodan (Merck, Research Labo-
ratory, West Point, PA). Cells were grown in minimal
essential medium with α-F12 with 10% fetal bovine
serum in a modified atmosphere of 95% air and 5% CO2
at 37°C. This cell line contains a wild type endogenous
p53 [17] and can be induced to mineralize in culture and
express genes associated with advanced stages of differen-
tiation. The ROS17/2.8 cells were stably transfected with
the plasmid PG-13-CAT (a kind gift of Dr. B. Vogelstein,
Johns Hopkins University, Baltimore, MD). This plasmid
encodes 13 copies of a p53 binding DNA sequence fused
to a CAT reporter gene)[17]. In the present studies cells
transfected with this plasmid (referred to as ROS-PG13)
cells were used to monitor transcriptional activity of
endogenous p53.
Cell Culture conditions & Treatment with 17β-Estradiol
Cells for E2 treatment were exposed to phenol red free
media before and during treatment with E2. The water-
soluble form, 17β-estradiol (Sigma, St. Louis, MO) was
used at the concentration of 10-11 M. Cells used for E2
treatment were exposed to 2% charcoal-treated serum
containing phenol red free media for 24 hours before
treatment with E2. For experiments requiring E2 for
longer than 24 hours, fresh media with E2 was main-
tained on cells. Unless otherwise mentioned, all experi-
ments were done using E2 at a final concentration of 10-
11 M. This concentration is based on results obtained with
our previous studies, where we saw maximal induction of
p53 at 10-11 M – 10-12 M [12]. Cells were treated for differ-
ent lengths of time ranging from 0–72 h.
Transient Transfections
For beta-catenin transfections, we used HA-β-catenin (WT
beta catenin) and S33Y β-catenin (a constitutively active
mutant), a kind gift of Dr. Ben-Ze'ev, Weizmann Institute,
Rehovot, Israel. Cells were transfected with Superfect
(Qiagen) in 10-cm plates for 24–48 h followed by protein
lysis. The total amount of DNA used was maintained
equally in these experiments. Equal amount of protein
was used for measurement of alkaline phosphatase and
CAT activity.
Measurement of CAT Activity
CAT activity of ROS-PG13 cells after treatment was used as
a measure of p53 DNA binding activity and reflected p53
function at any time point. Harvested cells were
suspended in buffered saline and then in a 0.25 M Tris
buffer pH 7.8, disrupted by 3 freeze-thaw cycles. The
supernatants were collected after centrifugation and
heated at 65°C for 10 minutes to inactivate cellular acety-
lase activity. Protein concentrations were measured with
the Bradford method and equal amounts of protein were
used in the assays. CAT activity was determined by means
of liquid scintillation counting, and was measured over a
linear range of chloramphenicol acetylation such that the
fraction acetylated was proportional to actual activity. All
measurements were carried out on triplicate samples.
Other details are as described earlier.
Measurement of Luciferase Activity
For reporter assays, cells were transfected with the beta-
catenin responsive firefly luciferase reporter plasmids
TopFlash (wild type promoter) or FopFlash (Mutant pro-
moter) (Upstate Biotechnologies) for 48 h. Three hours
after transfection, cells received 17-beta estradiol to a con-
centration of 10–11 M for the times indicated. Cells were
exposed to LiCl for 16 hours, lysed and equal amount of
protein was used for measuring luciferase activity. All
measurements were carried out on triplicate samples and
experiments were repeated at least thrice.
Immunofluorescence staining
Beta-catenin and p53 were visualized by indirect immu-
nocytochemistry using a rabbit anti beta catenin (Zymed
Laboratories Inc., San Francisco, CA.) or a mouse anti-p53
(1C12) (Cell Signaling Technology, Beverly, MA.) as the
primary antibodies. ROS-PG13 cells were plated on cover-
slips and treated with E2 as described above. Cells were
fixed in ice cold methanol and permeabilized for ten min-
utes. Cells were then blocked with 10% goat serum for 10
minutes room temperature. Samples were incubated for 1
hour with primary antibody followed by a-30 minute
incubation with a goat, anti-rabbit TRITC-conjugate or
goat, anti-mouse FITC-conjugate. Cells were then viewed
with a Nikon Eclipse 400 fluorescence microscope using
40× and 100× objectives. Digital images were captured
with a Spot digital camera (Diagnostic Instruments, Ster-
ling Heights, MI) using automated exposure times and
gain settings for the bright-field images. Dark-field fluo-
rescence images were captured using a gain setting of 16
and exposure times of 3 s for green and 1 s for red and
blue. The digital images were processed using the Image-
Pro Plus images analysis software package (Media Cyber-
netics, Silver Spring, MD).
Negative controls consisted of samples that were incu-
bated without the primary antibodies. All labeling
experiments were repeated at least three times and were
highly reproducible.Cancer Cell International 2005, 5:24 http://www.cancerci.com/content/5/1/24
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Immuno Blotting
Protein lysates were prepared using M-PER Reagent
(Pierce, Rockford, IL) combined with a protease inhibitor
cocktail, Complete Mini (Roche, Mannheim, Germany).
Twenty-five micrograms of each protein lysate was sub-
jected to 10% SDS-PAGE, and transferred to immun-Blot
PVDF membrane (Bio-Rad, Hercules, CA). Expression was
determined using rabbit anti beta catenin (Cell Signaling
Technology, MA) and HRP-goat anti rabbit conjugate
(Zymed Laboratories Inc.CA). Membranes were then
developed using enhanced chemiluminescence (Amer-
sham International, Amersham, Bucks, UK).
Alkaline Phosphastase
Alkaline phosphatase activity was measured using a quan-
titative colorimetric assay with para-nitrophenol phos-
phate as substrate using a commercially available kit
(Sigma Chemical Company, St. Louis, MO).
Statistical Analyses
The differences in the means of experimental results were
analyzed for their statistical significance with the one-way
ANOVA combined with a multiple comparison procedure
(Tukey Kramer multiple comparisons test).
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